ClinicalTrials.Veeva

Menu
R

Revival Research Institute | Troy, MI

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Rocatinlimab
BIIB059
Dupilumab
ESK-001
Remibrutinib
Litifilimab
CDX-0159
SCD-044
RO7790121
Orismilast

Parent organization

This site is a part of Revival Research Institute

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

19 of 36 total trials

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST)

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE)....

Enrolling
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: Litifilimab
Drug: Placebo

In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE)....

Invitation-only
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: BIIB059 (litifilimab)
Locations recently updated

The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in pa...

Enrolling
Hidradenitis Suppurativa
Drug: Placebo 1
Drug: Placebo 2

The main objective of the study will be to evaluate the efficacy of rocatinlimab compared with placebo at week 24 on the patient-reported outcome (PR...

Enrolling
Prurigo Nodularis
Drug: Placebo
Drug: Rocatinlimab

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are:*...

Enrolling
Plaque Psoriasis
Drug: ESK-001
Drug: Placebo

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with Atopic Dermatitis

Enrolling
Atopic Dermatitis
Biological: Barzolvolimab
Drug: Matching placebo

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.

Enrolling
Prurigo Nodularis
Other: Matching Placebo
Biological: barzolvolimab

The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (A...

Active, not recruiting
Atopic Dermatitis
Drug: Placebo
Drug: LY3454738

This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety...

Enrolling
Atopic Dermatitis
Eczema Atopic Dermatitis
Drug: Placebo
Drug: Camoteskimab

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in ar...

Active, not recruiting
Hidradenitis Suppurativa
Drug: Placebo
Biological: Lutikizumab

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

The purpose of this study is to assess the efficacy and safety of RO7790121 in participants with moderate to severe atopic dermatitis (AD).

Enrolling
Atopic Dermatitis
Drug: Placebo
Drug: RO7790121

The purpose of the study is to see if Clascoterone can help people with male pattern hair loss to recovery and see if the treatment is effective and...

Enrolling
Alopecia, Androgenetic
Drug: Clascoterone 5% solution
Drug: Vehicle solution

The main purpose of this study is to assess the efficacy of lebrikizumab versus placebo on skin lesions in adults and adolescent participants with at...

Not yet enrolling
Atopic Hand and Foot Dermatitis
Drug: Lebrikizumab
Drug: Placebo

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...

Enrolling
Atopic Dermatitis
Drug: PF-07264660
Drug: PF-07275315

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to...

Enrolling
Psoriasis
Severe Psoriasis
Drug: Open-Label ESK-001
Drug: Blinded ESK-001

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

This is a multicenter, randomized, double-blind, placebo-controlled study in subjects with moderate to severe plaque psoriasis.

Active, not recruiting
Moderate to Severe Plaque Psoriasis
Drug: Placebo
Drug: SCD-044_Dose 3

This is a Phase II, randomized, double-blind, placebo-controlled study in subjects with moderate to severe atopic dermatitis.

Active, not recruiting
Dermatitis, Atopic
Drug: SCD-044_Dose 3
Drug: SCD-044_Dose 1

Trial sponsors

Pfizer logo
Amgen logo
Celldex Therapeutics logo
A
Biogen logo
Janssen (J&J Innovative Medicine) logo
Lilly logo
Novartis logo
Sun Pharma logo
AbbVie logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems